Full-Time
Develops biopharmaceuticals for serious diseases
$126.7k - $206.9k/yr
Mid, Senior
Berkeley Heights, NJ, USA + 1 more
More locations: Tarrytown, NY, USA
Get referrals →
You have ways to get a Regeneron Pharmaceuticals referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 5 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its efforts. Regeneron generates revenue by selling its approved medicines and through licensing agreements, sharing costs and profits with partners in co-development projects. Unlike many competitors, Regeneron emphasizes strong research capabilities and strategic partnerships to stay ahead in the biotechnology field. The company's goal is to improve patient outcomes by delivering effective treatments.
Company Size
10,001+
Company Stage
IPO
Headquarters
Town of Greenburgh, New York
Founded
1988
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Wellness Program
Paid Vacation
Equity Awards
Annual Bonuses
Flexible Work Hours
Regeneron has announced the upcoming presentation of 27 abstracts, including 8 oral presentations on aflibercept injection 8 mg (EYLEA HD) in wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR) at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City.
Regeneron continues to invest heavily in its New York State operations, where an approximately $3.6 billion expansion of its Tarrytown campus is underway, creating 1,000 full-time, high-skill jobs and expanding research, preclinical manufacturing and support facilities.
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApproval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.Kenneth MendezPresident and Chief Executive Officer at the Asthma and Allergy Foundation of America“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives. The approval of this treatment offers patients more options and the chance to control their disease.”Alyssa Johnsen, M.D., Ph.D.Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi“CSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living. This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms. Dupixent has the potential to improve outcomes for CSU patients who previously had limited treatment options.”The US approval is based on data from two phase 3 clinical studies, Study A (n=136) and Study C (n=148), which included biologic-naïve patients aged 12 years and older who were symptomatic despite the use of antihistamines and assessed Dupixent as an add-on therapy to standard-of-care antihistamines, compared to antihistamines alone. Both studies met their primary and key secondary endpoints with Dupixent demonstrating reductions in itch severity and urticaria activity (a composite of itch and hives) compared to placebo at 24 weeks
Additionally, Regeneron is investing approximately $3.6 billion to expand its Tarrytown, New York facility, aiming to double its manufacturing capabilities nearly.
Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to broaden its capacity.